Exosome Therapy at Med Spas: What Is Legal in 2026

By Natasha Pomelova, Founder of MedicalSpaLocator.com and melov.ai — 15 years in pharmaceutical commercialization at Takeda, Amgen, Astellas, and Horizon Therapeutics.

Why Injectable Exosomes Are Not Approved

The FDA classifies injectable exosomes derived from human or animal cells as biologics requiring Biologics License Application (BLA) approval under 21 CFR 601. No company has received a BLA for an exosome product. The Center for Biologics Evaluation and Research (CBER) issued a public statement in 2019 explicitly warning that exosome products for injection require approval and that unapproved exosome products pose serious safety risks to patients.

The concern is straightforward: injectable exosomes carry cell signaling cargo (proteins, RNA, lipids) that can affect recipient cell behavior in ways that are not yet fully characterized. Without clinical trials demonstrating safety and efficacy, there is no basis for FDA approval — and no approval means no legal path for clinical administration.

The Warning Letter Pattern 2024–2026

FDA issued 6+ warning letters between 2024 and 2026 to exosome product manufacturers and distributors. The violations cited across these letters include: marketing unapproved biologics for clinical use, making therapeutic claims about treating specific conditions without clinical evidence, inability to assure sterility and product characterization, and distributing products to medical practices including med spas.

Critically, warning letters name intended clinical customers. Med spas that receive products from manufacturers who have received FDA warning letters face elevated enforcement risk — both from FDA directly and from state medical boards that monitor FDA communications.

What Med Spas Can Legally Offer

Topical Exosome Serums Explained

When an exosome-containing serum is applied to intact, unbroken skin, it functions as a cosmetic under FDA's regulatory framework. Cosmetics may make structure/function claims ("improves the appearance of skin texture") but cannot claim to treat, cure, or prevent any condition. Topical exosome serums are legal to sell and apply at med spas under these conditions.

The complication arises with microneedling. When needles break the skin barrier, the FDA considers substances applied to that disrupted surface to be entering the body through the injection route — equivalent in regulatory terms to an injectable product. Applying exosome serums to microneedled skin places those products in biologic/drug territory without any approval. This is a high-risk practice that combines the liability of injection administration with an unapproved product.

Risk Calculation for Med Spa Owners

Med spa owners offering injectable exosome treatments face compounding liability: FDA enforcement action, state medical board investigation, malpractice claims if a patient experiences an adverse event from an unapproved product, and reputational damage if enforcement becomes public. The enforcement environment has been active and is accelerating.

Legal alternatives exist that achieve similar regenerative goals. PRF (Platelet-Rich Fibrin) provides autologous growth factor delivery with a well-established safety profile — see our PRF treatment guide. Microneedling with FDA-cleared devices addresses skin quality without unapproved biologics. Biostimulators like Sculptra and Radiesse have robust clinical evidence and FDA approval.

MedicalSpaLocator.com lists 18,000+ verified providers across 1,000+ U.S. cities with compliant regenerative treatment options.